



**PROFICIENCY TESTING SERVICE
AMERICAN ASSOCIATION OF BIOANALYSTS**
205 West Levee St. ♦ Brownsville, TX 78520-5596
800-234-5315 ♦ 281-436-5357 ♦ Fax 713-781-5008

PARTICIPANT STATISTICS

SECOND QUADRIMESTER 2018

HIV MARKERS

| anti-HIV-1 or 1/2 Screening Method | Specimen 1 | | | Specimen 2 | | | Specimen 3 | | | Specimen 4 | | | Specimen 5 | | |
|------------------------------------|------------|------------------------|-----|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|
| | Neg | Pos | Ind | Neg | Pos | Ind | Neg | Pos | Ind | Neg | Pos | Ind | Neg | Pos | Ind |
| Abbott Architect HIV Ag/Ab | | 12 | | | 12 | | | 12 | | | 12 | | | 12 | |
| Alere Clearview Complete HIV 1/2 | 2 | 2 | | | 4 | | | 4 | | | 4 | | | 4 | |
| Alere Determine | 106 | 12 | | 1 | 117 | | 2 | 116 | | 118 | | | | 117 | |
| Bio-Rad Bioplex 2000, 2200 | 1 | 3 | | | 4 | | | 4 | | | 4 | | | 4 | |
| Bio-Rad GS HIV Combo Ag/Ab EIA | | 15 | | | 15 | | | 15 | | | 15 | | | 15 | |
| Bio-Rad HIV-1/2 Plus O EIA | 3 | | | | 3 | | | 3 | | | 3 | | | 3 | |
| Chembio HIV 1/2 STAT-PAK | 12 | | | | 12 | | | 12 | | | 12 | | | 12 | |
| Clearview Stat-Pak | 4 | 1 | | | 5 | | | 5 | | 3 | 2 | | | 4 | 1 |
| OraSure OraQuick Advance | 5 | | | | 5 | | | 5 | | | 5 | | | 5 | |
| Siemens Advia CHIV | | 4 | | | 4 | | | 4 | | | 4 | | | 4 | |
| Trinity Uni-Gold Recombigen | 7 | | | | 7 | | | 7 | | | 7 | | | 7 | |
| Total Population | 147 | 50 | | 1 | 196 | 0 | 3 | 194 | 0 | 195 | 2 | 0 | 195 | 1 | 0 |
| Flagging | | &&& | | *** | | *** | *** | | *** | | *** | *** | | *** | *** |

& 4th Generation Ag/Ab Combo kits reacted to the p24 antigen as would be expected. For Specimen 1 They were evaluated against both antigen and antibody. If your kit reports serology and antigen independently, you must report antigen detection separately or be flagged.

* Alere Determine users appear to correctly have identified the positive p24 Antigen, but have largely called the screen negative. Methods that report antigen and anti-HIV separately should have reported Negative for Specimen 1.

anti-HIV-1 or 1/2 Confirmation

| Confirmation Method | Specimen 1 | | | | Specimen 2 | | | | | | | | | |
|-----------------------------|------------|------------|------------|--------------------|--------------------|--------------------|----------|------------|-----------|------------|--------------------|--------------------|--------------------|------------|
| | Neg | Pos | Ind | Pos HIV 1/Neg HIV2 | Neg HIV 1/Neg HIV2 | Pos HIV 1/Pos HIV2 | Neg, TNP | Neg | Pos | Ind | Pos HIV 1/Neg HIV2 | Neg HIV 1/Neg HIV2 | Pos HIV 1/Pos HIV2 | Neg, TNP |
| Bio-Rad Geenius | 1 | | | | 8 | | | | | | 9 | | | |
| Trinity Uni-Gold Recombigen | 31 | | | | | | 1 | | 32 | | | | | |
| Total Population | 34 | 1 | 0 | 0 | 8 | 0 | 1 | 0 | 35 | 0 | 9 | 0 | 0 | 0 |
| Flagging | | *** | *** | *** | | *** | | *** | | *** | | *** | *** | *** |

anti-HIV Confirmation

| Confirmation Method | Specimen 3 | | | | Specimen 4 | | | | | | | | | |
|-----------------------------|------------|-----------|------------|--------------------|--------------------|--------------------|------------|-----------|------------|------------|--------------------|--------------------|--------------------|----------|
| | Neg | Pos | Ind | Pos HIV 1/Neg HIV2 | Neg HIV 1/Neg HIV2 | Pos HIV 1/Pos HIV2 | Neg, TNP | Neg | Pos | Ind | Pos HIV 1/Neg HIV2 | Neg HIV 1/Neg HIV2 | Pos HIV 1/Pos HIV2 | Neg, TNP |
| Bio-Rad Geenius | | | | 9 | | | | 1 | | | | | 5 | 3 |
| Trinity Uni-Gold Recombigen | | 32 | | | | | | 31 | | | | | | 1 |
| Total Population | 0 | 35 | 0 | 9 | 0 | 0 | 0 | 33 | 1 | 0 | 0 | 6 | 0 | 4 |
| Flagging | *** | | *** | | *** | *** | *** | | *** | *** | *** | | *** | |

anti-HIV Confirmation

| Confirmation Method | Specimen 5 | | | | | | |
|-----------------------------|------------|------------|------------|--------------------|--------------------|--------------------|----------|
| | Neg | Pos | Ind | Pos HIV 1/Neg HIV2 | Neg HIV 1/Neg HIV2 | Pos HIV 1/Pos HIV2 | Neg, TNP |
| Bio-Rad Geenius | 1 | | | | 5 | | 3 |
| Trinity Uni-Gold Recombigen | 31 | | | | | | 1 |
| Total Population | 33 | 1 | 0 | 0 | 6 | 0 | 4 |
| Flagging | | *** | *** | *** | | *** | |

p24 Antigen

| p24 Antigen Method | Specimen 1 | | | Specimen 2 | | | Specimen 3 | | | Specimen 4 | | | Specimen 5 | | |
|-------------------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|
| | Neg | Pos | Ind | Neg | Pos | Ind | Neg | Pos | Ind | Neg | Pos | Ind | Neg | Pos | Ind |
| Alere Determine | 4 | 114 | | | 114 | 4 | | 114 | 4 | | 116 | 2 | | 114 | 3 |
| Total Population | 4 | 119 | 0 | 119 | 4 | 0 | 119 | 4 | 0 | 121 | 2 | 0 | 119 | 3 | 0 |
| Flagging | *** | | *** | | *** | *** | | *** | *** | | *** | *** | | *** | *** |

Correct responses are defined as those reflecting agreement among 80% or more of all participants or referees. Unacceptable responses are indicated by "*****" on the Flagging line of each specimen.